试验内成本-效果分析中缺失数据的处理
Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: a Review with Future Guidelines
摘要:
成本效益分析(CEA)以及随机对照试验(RCT)越来越多地被设计用于收集资源使用和基于偏好的健康状况数据,以用于医疗保健技术评估。然而,由于这些措施的收集方式,它们很容易出现缺失数据,这可能最终影响到对干预措施是否物有所值的决定。我们研究了如何在基于RCT的CEA中处理缺失的成本和效果结局数据,用新的系统性综述(2009-2015,81篇文章)补充了之前的综述(涵盖2003-2009,88篇文章),重点关注两个不同的观点。首先,我们回顾了缺失数据的描述,用于处理它们的统计方法,以及这些方法的选择所依据的判断质量。其次,我们提供了关于如何提供缺失信息和相关方法的指南,以改进缺失数据的报告和处理。我们的综述表明,RCT内CEA中的缺失数据通常仍未得到充分处理,为支持所选方法而提供的总体信息水平很少令人满意。
英文摘要:
Cost-Effectiveness Analyses (CEAs) alongside randomised controlled trials (RCTs) are increasingly often designed to collect resource use and preference-based health status data for the purpose of healthcare technology assessment. However, because of the way these measures are collected, they are prone to missing data, which can ultimately affect the decision of whether an intervention is good value for money. We examine how missing cost and effect outcome data are handled in RCT-based CEAs, complementing a previous review (covering 2003-2009, 88 articles) with a new systematic review (2009-2015, 81 articles) focussing on two different perspectives. First, we review the description of the missing data, the statistical methods used to deal with them, and the quality of the judgement underpinning the choice of these methods. Second, we provide guidelines on how the information about missingness and related methods should be presented to improve the reporting and handling of missing data. Our review shows that missing data in within-RCT CEAs are still often inadequately handled and the overall level of information provided to support the chosen methods is rarely satisfactory.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。